NCT06703177

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

Phase IB/II Study of Safety, Tolerability and Efficacy of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 876 (estimated)
• Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with advanced solid tumors.

Conditions

• Advanced Solid Tumors

Interventions

Type	Name	Description
DRUG	SHR-1826	SHR-1826
DRUG	SHR-4642	SHR-4642
DRUG	SHR-9839	SHR-9839
DRUG	SHR-8068	SHR-8068
DRUG	Bevacizumab Injection	Bevacizumab Injection
DRUG	Fluorouracil Injection	Fluorouracil Injection
DRUG	Calcium Folinate Injection	Calcium Folinate Injection
DRUG	Adebrelimab Injection	Adebrelimab Injection
DRUG	Capecitabine tablets	Capecitabine tablets, oral.

Timeline

• Start date: 2025-02-18
• Primary completion: 2026-01-01
• Completion: 2027-07-01
• First posted: 2024-11-25
• Last updated: 2025-12-03

Locations

1 site across 1 country: China